Treatment of Alzheimer’s
Tech ID
P21-1237
Patent Status
Granted in India
Design Status
--
Technical Description
The present invention provides the synthesis of novel quinolinyl piperazine derivatives for the treatment of Alzheimer’s disease by dual inhibition of β-secretase (BACE1) and acetylcholineesterase (AChE).
Problems Addressed
- Aβ Accumulation in Brain
- Single Target Therapy
- Current Treatment Limitations
- Decreased Cholinergic Activity
TARGET AUDIENCE
- Healthcare & Medical Sector
- Pharmaceutical Industry
- Biotechnology Firms
- Research & Development
TECH FEATURES
- Affordable
- Novel Component
- Neurodegenerative Disease Treatment
- AChE, BuChE & BACE1 Inhibitors
- Final Edge Identification
- Enhanced BBB Permeability
P21-1237
Send download link to email.
Available For
Available for exclusive and non exclusive license
Sell off
Cost
—
Stage of Developments
Technology Validated
Contact Person
Mr. Lalit Ambastha
IP Bazzaar Technology Pvt. Ltd.
IP Bazzaar Technology Pvt. Ltd.
12 First Floor, National Park, Lajpat Nagar-IV,
New Delhi-110024, India
Tel: [+91] 11-26360036;
Fax: [+91] 11-26360037;
Mobile: [+91]9811367838;
Email: tech@ipbazzaar.com;
www.ipbazzaar.com
New Delhi-110024, India
Tel: [+91] 11-26360036;
Fax: [+91] 11-26360037;
Mobile: [+91]9811367838;
Email: tech@ipbazzaar.com;
www.ipbazzaar.com